CSL Limited (F:CSJ) — Market Cap & Net Worth
Market Cap & Net Worth: CSL Limited (CSJ)
CSL Limited (F:CSJ) has a market capitalization of $46.77 Billion (€40.00 Billion) as of April 17, 2026. Listed on the F stock exchange, this Germany-based company holds position #513 globally and #67 in its home market, demonstrating a -3.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CSL Limited's stock price €82.45 by its total outstanding shares 485151394 (485.15 Million).
CSL Limited Market Cap History: 2015 to 2026
CSL Limited's market capitalization history from 2015 to 2026. Data shows growth from $34.03 Billion to $46.77 Billion (5.54% CAGR).
CSL Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CSL Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.61x
CSL Limited's market cap is 3.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
18.55x
CSL Limited's market cap is 18.55 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $33.10 Billion | $7.96 Billion | $1.67 Billion | 4.16x | 19.78x |
| 2017 | $44.67 Billion | $8.60 Billion | $1.74 Billion | 5.19x | 25.69x |
| 2018 | $59.43 Billion | $10.27 Billion | $2.34 Billion | 5.79x | 25.41x |
| 2019 | $89.90 Billion | $12.13 Billion | $2.74 Billion | 7.41x | 32.86x |
| 2020 | $94.23 Billion | $13.26 Billion | $3.06 Billion | 7.11x | 30.76x |
| 2021 | $100.37 Billion | $10.27 Billion | $2.38 Billion | 9.78x | 42.26x |
| 2022 | $99.04 Billion | $10.49 Billion | $2.25 Billion | 9.44x | 43.93x |
| 2023 | $97.40 Billion | $13.17 Billion | $2.19 Billion | 7.39x | 44.40x |
| 2024 | $94.62 Billion | $14.69 Billion | $2.64 Billion | 6.44x | 35.81x |
| 2025 | $55.69 Billion | $15.43 Billion | $3.00 Billion | 3.61x | 18.55x |
Competitor Companies of CSJ by Market Capitalization
Companies near CSL Limited in the global market cap rankings as of April 17, 2026.
Key companies related to CSL Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $110.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #292 globally with a market cap of $77.51 Billion USD.
- Argen-X (F:1AE): Ranked #532 globally with a market cap of $44.01 Billion USD ( €37.64 Billion EUR).
- UCB SA (BR:UCB): Ranked #448 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.53 Billion | $435.65 |
| #292 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.51 Billion | $746.00 |
| #532 | Argen-X | F:1AE | $44.01 Billion | €712.00 |
| #448 | UCB SA | BR:UCB | $51.74 Billion | €258.70 |
CSL Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, CSL Limited's market cap moved from $34.03 Billion to $ 46.77 Billion, with a yearly change of 5.54%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €46.77 Billion | -16.02% |
| 2025 | €55.69 Billion | -41.15% |
| 2024 | €94.62 Billion | -2.86% |
| 2023 | €97.40 Billion | -1.65% |
| 2022 | €99.04 Billion | -1.32% |
| 2021 | €100.37 Billion | +6.52% |
| 2020 | €94.23 Billion | +4.81% |
| 2019 | €89.90 Billion | +51.28% |
| 2018 | €59.43 Billion | +33.03% |
| 2017 | €44.67 Billion | +34.96% |
| 2016 | €33.10 Billion | -2.74% |
| 2015 | €34.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 17th, 2026 the market cap of CSL Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.77 Billion USD |
| MoneyControl | $46.77 Billion USD |
| MarketWatch | $46.77 Billion USD |
| marketcap.company | $46.77 Billion USD |
| Reuters | $46.77 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more